Form 4: Kura Oncology's Chief Legal Officer Reports Stock Transactions

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports a stock purchase and sale executed under a pre-arranged Rule 10b5-1 trading plan and the Employee Stock Purchase Plan.

Summary

• Teresa Brophy Bair, the Chief Legal Officer of Kura Oncology, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On May 19, 2025, she sold 1,559 shares of common stock at a price of $5.96.
• This transaction was executed under a Rule 10b5-1 trading plan adopted on May 31, 2024.
• She also acquired 1,559 shares on May 17, 2025, through the Issuer's Employee Stock Purchase Plan.
• Following these transactions, Bair directly owns 107,948 shares of Kura Oncology stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an officer under a pre-arranged plan and employee stock purchase plan.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Key Dates

Keywords

Form 4, Kura Oncology, Beneficial Ownership, Teresa Brophy Bair, Stock Transaction, Rule 10b5-1, Employee Stock Purchase Plan